5 FDA decisions to watch in the fourth quarter of 2026
BioPharma DiveBioPharma Dive staffOctober 1, 2026
The next three months will feature anticipated decisions on a new kind of cancer immunotherapy, as well as medicines important to the futures of Roche, GSK and Gilead.